Abstract
Background The C-reactive protein–albumin–lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune function. We evaluated its association with survival in primary lung malignancies.
Methods Embase, PubMed, Scopus, and Web of Science were searched from inception to 18 September 2026. Risk of bias was assessed using the Quality In Prognosis Studies tool. Hazard ratios (HRs) were synthesized using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Sensitivity analyses, subgroup analyses, and meta-regression examined robustness and heterogeneity.
Results Eleven studies contributed 13 cohorts to the overall survival (OS) analysis and 8 cohorts from seven studies to a combined recurrence/progression-free survival (RFS/PFS) analysis. Lower CALLY was associated with poorer OS (HR 1.78, 95% CI 1.49–2.12; I²=71.6%) and poorer RFS/PFS (HR 1.60, 95% CI 1.40–1.84; I²=0%). Associations persisted in leave-one-out analyses. No statistically significant subgroup differences were detected. Funnel-plot asymmetry suggested small-study effects for OS and RFS/PFS. Seven studies had moderate and four had high overall risk of bias. The certainty of evidence was rated as low for both OS and RFS/PFS, primarily due to risk of bias, heterogeneity, and endpoint indirectness.
Conclusion Lower CALLY was associated with adverse survival outcomes in the current synthesis. Methodological limitations and variation in biomarker measurement and endpoint definitions restrict interpretation. Prospective validation using standardized measurements and clinically coherent outcomes is needed to establish incremental prognostic value and clinical utility.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only publicly available human data obtained from published studies identified through systematic searches of PubMed, Embase, Scopus, and Web of Science.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: kparastou{at}yahoo.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript
Abbreviations
- AUC
- area under the receiver operating characteristic curve
- CALLY
- C-reactive protein–albumin–lymphocyte
- C-index
- concordance index
- CAR
- C-reactive protein-to-albumin ratio
- CI
- confidence interval
- CRC
- colorectal cancer
- CRP
- C-reactive protein
- DLBCL
- diffuse large B-cell lymphoma
- DMFS
- distant metastasis-free survival
- GRADE
- Grading of Recommendations Assessment, Development and Evaluation
- HR
- hazard ratio
- ICI
- immune checkpoint inhibitor
- IQR
- interquartile range
- KM
- Kaplan–Meier
- LA-NSCLC
- locally advanced non-small cell lung cancer
- LC
- lung cancer
- LIPI
- lung immune prognostic index
- LPFS
- locoregional progression-free survival
- mGPS
- modified Glasgow Prognostic Score
- MLR
- monocyte-to-lymphocyte ratio
- MV
- multivariable
- NLR
- neutrophil-to-lymphocyte ratio
- NR
- not reported
- NSCLC
- non-small cell lung cancer
- OS
- overall survival
- PFS
- progression-free survival
- PLR
- platelet-to-lymphocyte ratio
- PNI
- prognostic nutritional index
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PROSPERO
- International Prospective Register of Systematic Reviews
- PSM
- propensity score matching
- QUIPS
- Quality In Prognosis Studies
- REML
- restricted maximum likelihood
- RFS
- recurrence-free survival
- ROC
- receiver operating characteristic
- RT
- radiotherapy
- SCLC
- small cell lung cancer
- SD
- standard deviation
- SE
- standard error
- TNM
- tumor–node–metastasis
- UV
- univariable.





